| Identification | Back Directory | [Name]
3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate | [CAS]
876170-44-4 | [Synonyms]
Sofinicline benzenesulfonate
3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-, Monobenzenesulfonate | [Molecular Formula]
C16H17Cl2N3O3S | [MDL Number]
MFCD28016491 | [MOL File]
876170-44-4.mol | [Molecular Weight]
402.29 |
| Hazard Information | Back Directory | [Uses]
Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC50=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD)[1]. | [References]
[1] Fleisher C, et al. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder[J]. Expert opinion on investigational drugs, 2014, 23(8): 1157-1163. DOI:10.1517/13543784.2014.934806 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|